CEO SUMMARY: Medicare’s decision to cease covering many pharmacogenomic tests puts as many as 19 million Americans who have genetic variations affecting their response to medications at risk. These medications are commonly prescribed for patients with cardiovascular disease, pain, depression, anxiety, and cancer. Meanwhile, medical centers such as Mayo Clinic are conducting clinical studies to collect evidence that appropriate use of pharmacogenomic tests can improve patient outcomes while also reducing the cost of care.
Medicare Ends Coverage for Some Pharmacogenomic Testing
Lack of genetic tests for medication aversion puts up to 19 millions Americans at risk
- By Mary Van Doren
- | From the Volume XXII NO. 9 - June 22, 2015 Issue
- Tags: aco, clinical lab, clinical laboratories, cpt, cpt 81225, FDA Clearance, genetic test, genetic testing, genetic testing for, genome project, genomic testing, genomics, hie, human genome, human genome project, laboratories, laboratory medicine, local coverage determination, Medicare, Medicare Administrative Contractor, personalized medicine, pharmacogenetic, pharmacogenetics, pharmacogenomic tests, pharmacogenomics, the human genome project
